Keywords: duska, thera, licenses, p2r, glaucoma, ip, therapeutics

Duska Thera licenses P2R glaucoma IP

Article | 27 June 2005

Print This

Duska Therapeutics has acquired the exclusive rights to a novel P2 receptor-based proprietary technology aimed at the development of a ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in